Literature DB >> 3023049

The 3' region of bovine leukemia virus genome encodes a trans-activator protein.

C A Rosen, J G Sodroski, L Willems, R Kettmann, K Campbell, R Zaya, A Burny, W A Haseltine.   

Abstract

The genome of bovine leukemia virus (BLV) contains several overlapping, long open reading frames 3' to the envelope gene. Experiments presented here show that the cDNA encompassing the X region open reading frames encodes a trans-activator function capable of increasing the level of gene expression directed by the BLV long terminal repeat sequences. This study provides further evidence of the structural and functional similarities of the bovine leukemia virus and the human T lymphotropic viruses, HTLV-I and HTLV-II.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3023049      PMCID: PMC1167156          DOI: 10.1002/j.1460-2075.1986.tb04538.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  27 in total

1.  Trans-activator gene of HTLV-II induces IL-2 receptor and IL-2 cellular gene expression.

Authors:  W C Greene; W J Leonard; Y Wano; P B Svetlik; N J Peffer; J G Sodroski; C A Rosen; W C Goh; W A Haseltine
Journal:  Science       Date:  1986-05-16       Impact factor: 47.728

2.  Synthesis of rabbit beta-globin in cultured monkey kidney cells following infection with a SV40 beta-globin recombinant genome.

Authors:  R C Mulligan; B H Howard; P Berg
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

3.  Experiments with cloned complete tumor-derived bovine leukemia virus information prove that the virus is totally exogenous to its target animal species.

Authors:  J Deschamps; R Kettmann; A Burny
Journal:  J Virol       Date:  1981-11       Impact factor: 5.103

4.  Immunoglobulin gene transcription is activated by downstream sequence elements.

Authors:  C Queen; D Baltimore
Journal:  Cell       Date:  1983-07       Impact factor: 41.582

5.  The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection.

Authors:  C M Gorman; G T Merlino; M C Willingham; I Pastan; B H Howard
Journal:  Proc Natl Acad Sci U S A       Date:  1982-11       Impact factor: 11.205

6.  Complete amino acid sequence of human T-cell leukemia virus structural protein p15.

Authors:  T D Copeland; S Oroszlan; V S Kalyanaraman; M G Sarngadharan; R C Gallo
Journal:  FEBS Lett       Date:  1983-10-17       Impact factor: 4.124

7.  Primary structure analysis of the major internal protein p24 of human type C T-cell leukemia virus.

Authors:  S Oroszlan; M G Sarngadharan; T D Copeland; V S Kalyanaraman; R V Gilden; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

8.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

9.  Chromosome integration domain for bovine leukemia provirus in tumors.

Authors:  R Kettmann; J Deschamps; D Couez; J J Claustriaux; R Palm; A Burny
Journal:  J Virol       Date:  1983-07       Impact factor: 5.103

10.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

View more
  13 in total

1.  Localization of sequences responsible for trans-activation of the equine infectious anemia virus long terminal repeat.

Authors:  L Sherman; A Gazit; A Yaniv; T Kawakami; J E Dahlberg; S R Tronick
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

2.  Proposed gag-encoded transcriptional activator is not necessary for Rous sarcoma virus replication or transformation.

Authors:  K Carlberg; K Beemon
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

3.  Transactivating potential of the 3' open reading frame of murine mammary tumor virus.

Authors:  P van Klaveren; P Bentvelzen
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

4.  Construction of a recombinant bovine leukemia virus vector for analysis of virus infectivity.

Authors:  D Derse; L Martarano
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

5.  Expression of the bovine leukemia virus X region in virus-infected cells.

Authors:  N R Rice; S L Simek; G C Dubois; S D Showalter; R V Gilden; R M Stephens
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

6.  Transcriptional activation of bovine leukemia virus in blood cells from experimentally infected, asymptomatic sheep with latent infections.

Authors:  D M Lagarias; K Radke
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

7.  Even transcriptionally competent proviruses are silent in bovine leukemia virus-induced sheep tumor cells.

Authors:  A Van den Broeke; Y Cleuter; G Chen; D Portetelle; M Mammerickx; D Zagury; M Fouchard; L Coulombel; R Kettmann; A Burny
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

Review 8.  Critical role of human T-lymphotropic virus type 1 accessory proteins in viral replication and pathogenesis.

Authors:  Björn Albrecht; Michael D Lairmore
Journal:  Microbiol Mol Biol Rev       Date:  2002-09       Impact factor: 11.056

9.  Amplification and analysis of specific DNA and RNA sequences of bovine leukemia virus from infected cows by polymerase chain reaction.

Authors:  M P Sherman; G D Ehrlich; J F Ferrer; J J Sninsky; R Zandomeni; N L Dock; B Poiesz
Journal:  J Clin Microbiol       Date:  1992-01       Impact factor: 5.948

10.  Identification of alternatively spliced mRNAs encoding potential new regulatory proteins in cattle infected with bovine leukemia virus.

Authors:  S Alexandersen; S Carpenter; J Christensen; T Storgaard; B Viuff; Y Wannemuehler; J Belousov; J A Roth
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.